1573008-96-4

Upstream product

• 90259-27-1 2-fluoro-6-methylbenzoic acid 
• 1427373-55-4 3-bromo-6-fluoro-2-methyl-benzoic acid 
• 1572516-10-9 5-bromo-3-(chlorosulfonyl)-2-fluoro-6-methylbenzoic acid 
• 150444-95-4 3-chloro-4,5-difluorobenzoic acid 
• 149144-05-8 3-chloro-4,5-difiuoro-aniline 
• 1573008-93-1 5-bromo-3-(chlorosulfonyl)-2-fluoro-6-methylbenzoyl chloride 
• 1572516-19-8 tert-butyl N-(3-chloro-4,5-difluoro-phenyl)carbamate 

Downstream Products

• 1572513-53-1 N-(3-chloro-4,5-difluorophenyl)-2-fluoro-6-methyl-3-[[(1R)-2,2,2-trifluoro-1-methylethyl]sulfamoyl]benzamide 
• 1572516-24-5 5-bromo-N-(3-chloro-4,5-difluorophenyl)-2-fluoro-6-methyl-3-[[(1R)-2,2,2-trifluoro-1-methylethyl]sulfamoyl]benzamide 

Relevant academic research and scientific papers

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.